• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Novel hepatitis C treatment may be cost-effective in early stages of fibrosis

byAnees DaudandJames Jiang
November 27, 2015
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

 

1. Based on modeling data from the treatment trials of HCV genotype 1 infection with the newer agents, treating even at the early stages of fibrosis is cost-effective (spending <$50,000 per quality-adjusted life year was considered cost-effective) compared to waiting for late stages of fibrosis.

2. Treating about 50% of the eligible patient population at any stage of fibrosis would cost about $50 billion, compared to about $30 billion if the 50% of advanced fibrosis stage patients were treated.

Evidence Rating Level: 2 (Good)

Study Rundown: Hepatitis C (HCV) infection is the leading cause of liver-related deaths, hepatocellular carcinoma, and liver transplants in the US. The latest therapies, which include HCV nucleotide analogue nonstructural protein 5A and B inhibitors, lead to a greater than 90% cure rate for HCV genotype 1, but cost about $1000 per day or more. While there are studies that show these newer drugs can be cost-effective, the optimal time for treatment, in regards to level of fibrosis (F0 = no fibrosis, F4 = cirrhosis) is not known. This analysis, which modeled treatment of HCV at all stages of liver fibrosis compared to advanced stages, was conducted to help determine the optimal level of liver fibrosis at which to introduce HCV therapies from a cost-benefit perspective. The results suggested that, even at the early stages of fibrosis, treating HCV infection with the newer drugs was cost-effective in the long run (spending <$50,000 per quality-adjusted life year was considered cost-effective). Also, treating about 50% of the eligible patient population at any stage of fibrosis would cost about $50 billion, compared to about $30 billion if the 50% of advanced fibrosis stage patients were treated.

The model had several limitations. There was limited data on the long-term efficacy of an initial sustained-virologic response, which may overestimate the savings. Additionally, the models were based off of meta-analyses of studies, which may be “best-case scenarios” and may not accurately reflect real life scenarios. Additionally, the costs of the drugs may be different based on health network negotiations, and may change over a few years, which would make the results difficult to interpret.

Click to read the study in JAMA Internal Medicine

RELATED REPORTS

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

Medical cannabis provides little improvement to sleep in chronic pain patients

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

Relevant Reading: Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States

In-Depth [decision-analytic model]: Investigators modeled the approved newer treatments for HCV genotype 1 amongst treatment-naĂŻve Americans at different levels of fibrosis. The fibrosis levels were defined as follows: F0 = no fibrosis, F1 = portal fibrosis without septa, F2 = portal fibrosis with rare septa, F3 = numerous septa without cirrhosis, F4 = cirrhosis. The likelihood of sustained virologic response (SVR) and discontinuation of therapy were based off of meta-analyses of the clinical trials that initially evaluated this therapy.

Specifically, the model evaluated sofosbuvir-ledipasvir treatment for 8 or 12 weeks (depending on viral load). The modeled natural progression of disease and mortality were also based off the published literature. The model outcomes were quality-adjusted life years (QALYs) and health care cost. Treating any stage of fibrosis compared to just F3 and F4 produced a QALY gain of 0.73. The cost, however, of treating all fibrosis stages lead to a cost increase of $39,475 per QALY gained.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Previous Post

Glyburide as effective as insulin for gestational diabetes [Classics Series]

Next Post

Lopinavir-ritonavir prophylaxis not superior to lamivudine in preventing HIV in breastfeeding infants [ANRS 12174 trial]

RelatedReports

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
StudyGraphics

#VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis

May 27, 2022
Parental cannabis use increasing, cigarette use decreasing
Chronic Disease

Medical cannabis provides little improvement to sleep in chronic pain patients

May 27, 2022
Genetic risk assessment for Alzheimer’s disease does not increase anxiety, depression or stress
Chronic Disease

Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms

May 26, 2022
#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly
StudyGraphics

#VisualAbstract: Ruxolitinib shows long-term safety and efficacy in inadequately controlled polycythaemia vera without splenomegaly

May 26, 2022
Next Post
Government-funded initiatives provide important supports to low-income HIV patients

Lopinavir-ritonavir prophylaxis not superior to lamivudine in preventing HIV in breastfeeding infants [ANRS 12174 trial]

Uterine cavity lavage may detect gynecological malignancies

Uterine cavity lavage may detect gynecological malignancies

Interventional neuroradiology procedures may deliver lens radiation doses exceeding safe thresholds

Interventional neuroradiology procedures may deliver lens radiation doses exceeding safe thresholds

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • #VisualAbstract: Bimekizumab shows a favourable 2-year safety profile in patients with moderate to severe plaque psoriasis
  • Medical cannabis provides little improvement to sleep in chronic pain patients
  • Alzheimer disease in individuals with Down syndrome has similar variability in age of onset and mortality rate as autosomal dominant forms
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.